Exelixis

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exelixis reports robust Q4 performance, eyes pipeline expansion in 2023

Exelixis showed strong revenue growth and strategic wins in Q4 2022.
The company faces challenges with net losses and gross to net expectations.
Opportunities lie in pipeline advancement, zanzalintinib development, and new business activities.
Overall, Exelixis remains focused on growth and innovation in the pharmaceutical sector.

Exelixis reports strong Q1 earnings, advances promising pipeline programs

Exelixis showcased robust financials and a promising pipeline in Q1, driven by strong CABOMETYX performance and R&D advancements.
Challenges include gross to net impact and delays in share repurchase program purchases, with key decisions pending on XL102 progress.
Opportunities lie in expanding Phase 3 trials, focusing on unmet needs, and maintaining a strategic approach to asset prioritization for future growth.

Exelixis reports robust Q2 earnings, advances pipeline for growth

Exelixis delivered a strong Q2 performance with significant revenue and income figures, driven by the success of CABOMETYX and ongoing R&D efforts.
The company's market leadership, legal resolution with Teva, and commitment to innovation position it well for future growth and competitive advantage.
While facing challenges in program decision-making and market penetration, Exelixis has opportunities in pipeline advancement, regulatory discussions, and investor engagement.
Overall, Exelixis remains focused on its mission to help cancer patients, with a positive outlook and strategic initiatives in place for continued success.

Exelixis reports strong Q3 earnings, faces guidance challenges and growth opportunities

Exelixis had a strong Q3 2023 with robust revenue growth from CABOMETYX and ongoing operational support.
The company faces challenges in financial guidance adjustments and questions on FDA expectations and legal proceedings.
Opportunities lie in potential growth for CABOMETYX, advancing pipeline assets, and expanding into new indications.
Overall, Exelixis remains focused on innovation, collaboration, and supporting cancer patients with upcoming R&D Day excitement.

Exelixis reports robust 2023 performance, eyes growth through collaborations

Exelixis had a strong financial performance in 2023, driven by the cabozantinib franchise and strategic initiatives.
While facing challenges such as access to therapies and treatment variations, the company is well-positioned for growth.
Opportunities lie in collaborations, regulatory progress, and innovative drug development, positioning Exelixis for future success.

Exelixis reports strong Q1 earnings, focuses on pipeline advancement

Exelixis had a robust Q1 2024 with revenue and demand growth for Cabozantinib franchise.
Company is focused on advancing new indications, returning capital to shareholders, and pipeline development.
Challenges include study criteria, market capture, and capital allocation decisions.
Exciting opportunities lie in Zanza's potential, new combinations, and market growth prospects.

Exelixis excels in Q2 with cabozantinib driving revenue growth

Exelixis delivered a strong Q2 performance driven by cabozantinib franchise. Despite challenges in a competitive landscape, the company's focus on pipeline assets and commercial success presents growth opportunities. With increased revenue guidance and strategic initiatives, Exelixis is poised for continued success.

Exelixis excels in Q3 2024 with revenue growth and increased guidance

Exelixis delivered a strong performance in Q3 2024, marked by revenue growth, profitability, and increased guidance for the full year. The company's financial stability, strategic focus on oncology, and strong cash position provide a solid foundation for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Axsome Therapeutics

Exelixis is using its expertise in cancer medicines to move beyond its current best-selling product. Axsome Therapeutics should look like a very different company within the next few years.

2 Top Biotech Stocks Defying the Bear Market

Exelixis (EXEL) enters into a license agreement with Insilico Medicine for ISM3091, a potentially best-in-class USP1 inhibitor.

Exelixis (EXEL) Gets Rights for Tumor Candidate From Insilico

Exelixis Inc. EXEL, -0.54% is licensing the global rights to develop and commercialize an investigational cancer treatment that was derived from Insilico Medicine's generative artificial intelligence drug-discovery platform, the companies announced Tuesday. The cancer therapy, ISM3091, is an inhibitor of USP1 and is being studied for its potential to treat BRCA-mutant tumors, which include forms of ovarian, prostate and breast cancer.

Exelixis to license Insilico AI-designed cancer drug

ALAMEDA, Calif. & NEW YORK--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Insilico Medicine (“Insilico”) today announced that the companies have entered into an exclusive license agreement granting Exelixis global rights to develop and commercialize ISM3091, a potentially best-in-class small molecule inhibitor of USP1, which has emerged as a synthetic lethal target in the context of BRCA-mutated tumors. Under the terms of the agreement, Insilico granted Exelixis an exclusive, worldwide lic.

Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor

LUND, SE / ACCESSWIRE / September 07, 2023 / BioInvent International (STO:BINV) Collaboration focuses on novel antibodies for use in immuno-oncology therapeutics Target and antibody discovery performed using BioInvent's proprietary n-CoDeR® antibody library and F.I.R.S.T™ screening platform Lund, Sweden - September 7, 2023 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has achieved a research milestone event in its exclusive option and license agreement with Exelixis, Inc. (Nasdaq: EXEL) involving an undisclosed target, triggering a milestone payment of USD 1 million to BioInvent. BioInvent and Exelixis entered into a collaboration and license agreement in June 2022, focused on the identification and development of novel antibodies for use in immuno-oncology therapeutics.

BioInvent announces achievement of a research milestone event in its collaboration with Exelixis triggering a USD 1 million milestone payment

Illumina

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?

EXEL vs. ILMN: Which Stock Is the Better Value Option?

Exelixis' (EXEL) lead drug Cabometyx maintains momentum on consistent demand. Its efforts to develop additional drugs to expand its portfolio are poised to reap rewards for the company.

Exelixis (EXEL) Stock Gains 41.8% So Far in 2023: Here's Why

Arcellx

ANI Pharma

Dynavax Technologies

Vanda Pharmaceuticals

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position EXEL, DVAX, ACLX, ANIP and VNDA well amid volatility.

5 Biotech Stocks to Buy as New Drug Approvals Drive Industry Prospects

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?

Why Is Exelixis (EXEL) Up 10.6% Since Last Earnings Report?

Exelixis issued two important releases regarding its lead molecule cabozantinib, showing positive results in prostate cancer and advanced pancreatic and extra-pancreatic neuroendocrine tumors. The company's finances and liquidity are solid, with positive earnings and a healthy balance sheet. Despite a strong Q2, Exelixis left its guidance unchanged, prompting questions about near-term future growth prospects.

Exelixis: Predominantly Single Molecule Cancer Franchise (Rating Downgrade)

Fabrinet

Freshworks

H&R Block

Parsons Corp

We have narrowed our search to five mid-cap stocks that have provided double-digit returns in the past month. These are: FN, FRSH, HRB, EXEL, PSN.

Top 5 High-Flying Mid-Cap Stocks Despite a Volatile August

Phase 3 CABINET study, using CABOMETYX to treat patients with advanced pancreatic cancer and advanced pancreatic neuroendocrine tumors, stopped early due to overwhelming efficacy. Results from the phase 3 CABINET study are to be discussed with the FDA for the possibility of being able to file a regulatory application of CABOMETYX for these patient populations. Detailed results from the phase 3 CABINET study are to be presented at an upcoming medical meeting in 2023.

Exelixis: Positive Pancreatic Cancer Data Brings 2 Big Catalysts On Deck

Exelixis' (EXEL) phase III CABINET study shows dramatic improvement in efficacy in advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic neuroendocrine tumors.

Exelixis (EXEL) Late-Stage Study in Pancreatic Tumors Positive

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board (DSMB) unanimously recommended to unblind and stop the phase 3 CABINET pivotal trial early due to a dramatic improvement in efficacy that was observed at an interim analysis. CABINET is evaluating cabozantinib (CABOMETYX®) compared with placebo in patients with either advanced pancreatic neuroendocrine tumors (pNET) or adv.

Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced it has appointed Amy Peterson, M.D., its next Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer. Dr. Peterson is a veteran oncology drug development leader whose experience includes senior clinical development and operational roles at Genentech, Medivation, BeiGene and CytomX. She joins Exelixis as the company accelerates development of its product pipeline and builds on.

Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

Oppenheimer has raised its Exelixis Inc. price target to $29 from $25, citing the biotech's Phase 3 CONTACT-02 trial evaluating Cabozantinib in combination with Atezolizumab.

Exelixis stock price raised to $29 vs. $25 at Oppenheimer

Amgen

ImmunoGen

The world may be on the mend from the grip of the global pandemic, but the consistent drumbeat for medical innovation remains as unyielding as ever. Amid this backdrop, Biotech stocks present a beacon of hope for humanity and a compelling avenue for savvy investors.

These Are the ONLY 3 Biotech Stocks to Consider in August 2023

Exelixis (EXEL) and partner Ipsen's phase III CONTACT-02 study meets one of the two primary endpoints in prostate cancer patients.

Exelixis' (EXEL) Prostate Cancer Study Meets Primary Endpoint

ALAMEDA, Calif. & PARIS--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the global phase 3 CONTACT-02 pivotal trial met one of two primary endpoints, demonstrating a statistically significant improvement in progression-free survival (PFS) at the primary analysis. CONTACT-02 is evaluating cabozantinib (CABOMETYX®) in combination with atezolizumab compared with a second novel hormonal therapy in patients with metastatic castration-resista.

Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?

EXEL or ILMN: Which Is the Better Value Stock Right Now?

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

iShares Nasdaq Biotechnology ETF

The biotech sector, iShares Biotechnology ETF NASDAQ: IBB, has been trading in a tight consolidation for several months. The ETF has a 50-day range of $124.38 and $131.81.

3 Strong Biotech Performers To Watch As Sector Nears Breakout

Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surging Earnings Estimates Signal Upside for Exelixis (EXEL) Stock

Jazz Pharmaceuticals

The biotech industry proved itself resilient in the face of the COVID-19 pandemic. With research from Mckinsey, venture capitalist ( VC ) companies increased investments from 2,200 in 2016 to 3,100 in 2021 in biotechnology (biotech) startups.

3 Biotech Stocks You'll Regret Not Buying Soon

Exelixis (EXEL) beats second-quarter 2023 earnings and sales estimates as Cabometyx drives growth in approved indications.

Exelixis (EXEL) Q2 Earnings Top, Cabometyx Drives Growth

Exelixis, Inc. (NASDAQ:EXEL ) Q2 2023 Earnings Conference Call August 1, 2023 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs and Investor Relations Michael Morrissey - President and Chief Executive Officer Christopher Senner - Executive Vice President and Chief Financial Officer P.J. Haley - Executive Vice President, Commercial Dana Aftab - Chief Scientific Officer Vicki Goodman - Chief Medical Officer Peter Lamb - Chief Scientific Officer Conference Call Participants Asthika Goonewardene - Truist Jason Gerberry - Bank of America Securities Michael Schmidt - Guggenheim Andy Hsieh - William Blair Jay Olson - Oppenheimer Silvan Tuerkcan - JMP Securities Etzer Darout - BMO Capital Markets Derek Archila - Wells Fargo Joseph Catanzaro - Piper Sandler Jeffrey Hung - Morgan Stanley Alex Bouilloux - Barclays Stephen Willey - Stifel Chris Shibutani - Goldman Sachs Yaron Werber - TD Cowen Operator Good day, ladies and gentlemen, and welcome to the Exelixis Secod Quarter 2023 Financial Results Conference Call.

News for Exelixis Stock (EXEL)